| Name | Title | Contact Details |
|---|
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Integrated Health Network (IHN) of Wisconsin is the state’s first multi-system, clinically integrated accountable care network and one of the first in the United States. It is a consortium of independent health systems, hospitals and physicians working together to improve the quality, efficiency and value of health care. Since its launch in 2010, IHN has been transforming health care delivery with our clinically integrated network of leading health care providers and our sophisticated infrastructure for data analytics. The result is a model that delivers high quality health care and the cost savings of a narrow network, combined with the scale and value only possible through the breadth of a larger system.
Western Missouri Medical Center (WMMC) is a fully-accredited acute care facility located in Warrensburg, Missouri. A not-for-profit county Medical Center, WMMC offers comprehensive health care services to residents of Johnson County and west central Missouri. Through collaborating with our medical staff and integrating advanced technology, WMMC continues to grow as a progressive Medical Center that will continue to meet the evolving needs of the greater community.
MG&G Advertising is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Gateway Learning Group, we cultivate learning, language, behavior and social skills for individuals with Autism and other special needs. Using the principles of Applied Behavior Analysis (ABA) we design and implement an individualized therapy program for each child based on his or her particular needs and interests. Our therapists are experienced in a full range of the best treatments available including Verbal Behavior, Pivotal Response Treatments, Discrete Trial Training, and the Early Start Denver Model. To provide comprehensive support for our clients and their families, we also collaborate with educators and health professionals. Most of all, we love working with each child and enjoy sharing in their sense of pride, joy and accomplishment as they succeed.